The scenario where adding phentermine makes the strongest case is this: a patient on maximum tirzepatide dosing for at least 6 months, with a documented weight loss plateau lasting 8 or more weeks, who has optimized diet, exercise, sleep, and stress management, and whose provider has ruled out medical causes for the plateau (thyroid dysfunction, medication interactions, fluid retention)
In recent years, GLP-1 medications like Ozempic have progressed from a specialised diabetes treatment into a more widespread weight loss tool used by a wide range of people globally
Plaintiffs in these cases seek compensation for health issues, including cancer, caused by PFAS exposure, as well as environmental contamination claims
But there is still a change to be made where people should be better at listening to what a person say and what ideas they say
GLP-1 receptor agonists with demonstrated cardiovascular benefit in people with type 2 diabetes include liraglutide, 227 semaglutide, 229 and dulaglutide
More sustained improvements such as better grip strength, steadier hand function, and improved nerve conduction markers tend to appear over 6 to 12 weeks in clinical studies
